$1.10 -0.06 (%) Synthetic Biologics Inc - AMEX

Feb. 12, 2016 | 04:00 PM

Partner Headlines

  1. Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)

    Benzinga | Oct. 21, 2015 | 07:00AM EST
  2. Synthetic Biologics' Novel IBS-C Program Featured in American College of Gastroenterology Poster

    Benzinga | Oct. 20, 2015 | 15:31PM EST
  3. Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial

    Benzinga | Sep. 28, 2015 | 06:57AM EST
  4. Synthetic Biologics Says First Analysis Shows SYN-004 Protects Microbiome from IV Antibiotics Damage in Humanized Pig Model

    Benzinga | Sep. 21, 2015 | 06:59AM EST
  5. Insiders Are Buying Freeport McMoRan and Phillips 66

    GuruFocus | Sep. 11, 2015 | 16:00PM EST
  6. Benzinga's M&A Chatter for Wednesday August 26, 2015

    Benzinga | Aug. 26, 2015 | 19:25PM EST
  7. Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More

    Benzinga | Aug. 10, 2015 | 12:29PM EST
  8. Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria

    Benzinga | Aug. 10, 2015 | 06:31AM EST
  9. Market Update: Thursday's Mid-Day Movers, Greece, Iran, IPOs And More

    Benzinga | Jul. 16, 2015 | 14:17PM EST
  10. Monday's Mid-Day Movers: Greece's Bank Shuts Down; Puerto Rico Unable To Pay Debts

    Benzinga | Jun. 29, 2015 | 13:28PM EST
  11. First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

    Benzinga | Jun. 12, 2015 | 06:59AM EST
  12. Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infect

    Benzinga | Dec. 22, 2014 | 06:59AM EST
  13. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  14. Earnings Scheduled For November 14, 2014

    Benzinga | Nov. 14, 2014 | 05:05AM EST
  15. Synthetic Biologics Issues UCLA Report of Prelim. Positive Topline Efficacy, Safety Results from Phase II Study of Trimesta

    Benzinga | Apr. 29, 2014 | 15:46PM EST
  16. Morning Market Movers

    Benzinga | Mar. 31, 2014 | 09:40AM EST
  17. Earnings Scheduled For March 31, 2014

    Benzinga | Mar. 31, 2014 | 05:03AM EST
  18. Intrexon: Living Better Through Synthetic Biology?

    IBD | Jan. 28, 2014 | 14:03PM EST
  19. Morning Market Losers

    Benzinga | Dec. 12, 2013 | 09:59AM EST
  20. Synthetic Biologics Prices 11.5M Share Offering at $1.00/Share

    Benzinga | Dec. 11, 2013 | 21:14PM EST
  21. Synthetic Biologics, Intrexon Initiate Development of Novel Biologics for a Subset of Patients Suffering from IBS

    Benzinga | Dec. 9, 2013 | 16:29PM EST
  22. Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes

    Benzinga | Dec. 7, 2013 | 20:06PM EST
  23. Intrexon IPO Prices High After Upsizing; Stock Soars

    IBD | Aug. 8, 2013 | 12:28PM EST
  24. Synodon Inc. - A Breakthrough Technology For Pipeline Safety

    GuruFocus | Jan. 28, 2013 | 10:46AM EST
  25. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,900 Shares

    GuruFocus | Jan. 7, 2013 | 10:36AM EST
  26. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,000 Shares

    GuruFocus | Jan. 4, 2013 | 11:08AM EST
  27. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman

    Benzinga | May. 11, 2012 | 01:02AM EST
  28. Adeona Becomes Synthetic Biologics

    Benzinga | Feb. 16, 2012 | 01:14AM EST
Trading Center